Isofol Medical reported the Q4 results earlier today. The development of the research portfolio is progressing according to plan and costs were in line with expectations. Our fair value (base case) remains unchanged at SEK 38 per share, offering a substantial upside from current levels. Bull and bear case are SEK 48 and SEK 18 per share.